Get the Stockscreener App
1.21
4.31%
0.05
Scynexis Inc stock is traded at $1.21, with a volume of 160.62K.
It is up +4.31% in the last 24 hours and down -7.63% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$1.16
Open:
$1.14
24h Volume:
160.62K
Relative Volume:
0.73
Market Cap:
$44.01M
Revenue:
$135.87M
Net Income/Loss:
$72.20M
P/E Ratio:
0.8521
EPS:
1.42
Net Cash Flow:
$45.09M
1W Performance:
+13.08%
1M Performance:
-7.63%
6M Performance:
-34.95%
1Y Performance:
-39.50%
1-Day Range:
$1.14
$1.24
1-Week Range:
$1.02
$1.24
52-Week Range:
$0.9006
$3.07
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
1.21 | 44.01M | 135.87M | 72.20M | 45.09M | 1.42 |
|
ZTS
Zoetis Inc
|
171.46 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.54 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.545 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.68 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
122.91 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World
Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.
SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com
SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times
SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan
SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World
SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St
Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com
Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com
SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com
SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle
SCYNEXIS announces new $50 million equity sales agreement - Investing.com India
SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. In - GuruFocus.com
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving AverageShould You Sell? - MarketBeat
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - The Manila Times
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82 - MarketBeat
CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha
Potential Price Increase for Synopsys, Inc. (SNPS) After Recent Insider Activity - Knox Daily
Scynexis CEO acquires $27,400 in company stock By Investing.com - Investing.com Canada
Syncona Advances Share Buyback, Bolsters Treasury Shares - TipRanks
Xero buys South African firm for $115m in 'departure' - New Zealand Herald
SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Buys 20,000 Shares - MarketBeat
Scynexis CEO acquires $27,400 in company stock - Investing.com
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
2.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):